Innate and Cellular Immune Response to the Ebola Vaccine Ad26.ZEBOV, MVA-BN-Filo: An Ancillary Study of the EBL2001 Phase 2 Trial

Christine Lacabaratz, Mélany Durand, Aurélie Wiedemann, Emile Foucat, Mathieu Surénaud, Corinne Krief, Lydia Guillaumat, Cynthia Robinson, Kerstin Lühn, Viki Bockstal, Rodolphe Thiébaut, Laura Richert, Yves LévyThe Journal of Infectious Diseases 2024 · DOI

Abstract

This study provides unique insights into the in vivo contribution of proliferation/cytotoxic CD8+ T cells and inflammation to the Ad26.ZEBOV, MVA-BN-Filo vaccine-induced potency. Clinical Trials Registration. NCT02416453.
BibTeX
@article{lacabaratz2024innate,
  author = {Christine Lacabaratz and Mélany Durand and Aurélie Wiedemann and Emile Foucat and Mathieu Surénaud and Corinne Krief and Lydia Guillaumat and Cynthia Robinson and Kerstin Lühn and Viki Bockstal and Rodolphe Thiébaut and Laura Richert and Yves Lévy},
  title = {{Innate and Cellular Immune Response to the Ebola Vaccine Ad26.ZEBOV, MVA-BN-Filo: An Ancillary Study of the EBL2001 Phase 2 Trial}},
  journal = {The Journal of Infectious Diseases},
  year = {2024},
  doi = {10.1093/infdis/jiae360},
}

Loading related content...

Figure